During the last session, Cardiol Therapeutics Inc (NASDAQ:CRDL)’s traded shares were 0.35 million, with the beta value of the company hitting 0.98. At the end of the trading day, the stock’s price was $2.02, reflecting an intraday gain of 1.00% or $0.02. The 52-week high for the CRDL share is $3.12, that puts it down -54.46 from that peak though still a striking 67.33% gain since the share price plummeted to a 52-week low of $0.66. The company’s market capitalization is $139.38M, and the average trade volume was 500.78K shares over the past three months.
Cardiol Therapeutics Inc (NASDAQ:CRDL) trade information
Cardiol Therapeutics Inc (CRDL) registered a 1.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.00% in intraday trading to $2.02, hitting a weekly high. The stock’s 5-day price performance is 9.19%, and it has moved by -15.83% in 30 days. Based on these gigs, the overall price performance for the year is 152.82%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cardiol Therapeutics Inc (CRDL) estimates and forecasts
Statistics show that Cardiol Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Cardiol Therapeutics Inc (CRDL) shares have gone up 143.02% during the last six months, with a year-to-date growth rate less than the industry average at -3.03% against 13.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 16.52%. While earnings are projected to return -9.82% in 2024.
CRDL Dividends
Cardiol Therapeutics Inc is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.